The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1373
September 19, 2011
View Complete Issue         Table of Contents 2019 
Fidaxomicin (Dificid) for Clostridium Difficile Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Fidaxomicin (Dificid) for Clostridium Difficile Infection
September 19, 2011 (Issue: 1373)
The FDA has approved fidaxomicin (Dificid – Optimer), a new oral macrolide antibiotic, for treatment of Clostridium difficile-associated diarrhea in patients ≥18 years old. The incidence and severity of C. difficile infection (CDI) have...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fidaxomicin (Dificid) for Clostridium Difficile Infection
Article code: 1373a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.